Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved

Journal of Cachexia, Sarcopenia and Muscle

Volumn , Issue , 2015, Pages 132-143

  Chen, Ji An ^a,b   Splenser, Andres ^b   Guillory, Bobby ^b   Luo, Jiaohua ^a,b   Mendiratta, Meenal ^b   Belinova, Blaga ^b   Halder, Tripti ^b   Zhang, Guohua ^c   Li, Yi Ping ^c   Garcia, Jose M ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cachexia; Cancer; Ghrelin; Growth hormone; Muscle

Indexed keywords

ATROGIN 1; CCAAT ENHANCER BINDING PROTEIN BETA; CISPLATIN; GHRELIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; MUSCLE RING FINGER 1 PROTEIN; MYOD PROTEIN; MYOGENIN; MYOSIN HEAVY CHAIN; MYOSTATIN; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CACHEXIA; CANCER MORTALITY; CANCER TRANSPLANTATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; FOOD INTAKE; GRIP STRENGTH; IN VITRO STUDY; IN VIVO STUDY; LEAN BODY WEIGHT; LEWIS CARCINOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE MASS; MUSCLE WEAKNESS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION; WEIGHT CHANGE;

EID: 84982179410     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12023     Document Type: Article

References (52)

1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489–495.
2. Utech AE, Tadros EM, Hayes TG, Garcia JM. Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle 2012; 3: 245–251.
3. Little JP, Phillips SM. Resistance exercise and nutrition to counteract muscle wasting. Appl Physiol Nutr Metab 2009; 34: 817–828.
4. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17: 3299–3306.
5. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999; 129: 227S–237S.
6. Cai D, Frantz JD, Tawa NE, Jr., Melendez PA, Oh BC, Lidov HG et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004; 119: 285–298.
7. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 2012; 16: 153–166.
8. Garcia JM, Scherer T, Chen JA, Guillory B, Nassif A, Papusha V et al. Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice. Endocrinology 2013; 154: 3118–3129.
9. Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001; 142: 3292–3301.
10. Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 2005; 90: 2920–2926.
11. Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 2013; 21: 129–137.
12. Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab 1998; 83: 320–325.
13. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 57–66.
14. Garcia JM, Polvino WJ. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 2009; 19: 267–273.
15. Kos K, Harte AL, O'Hare PJ, Kumar S, McTernan PG. Ghrelin and the differential regulation of des-acyl (DSG) and oct-anoyl ghrelin (OTG) in human adipose tissue (AT). Clin Endocrinol (Oxf). 2009; 70: 383–389.
16. Porporato PE, Filigheddu N, Reano S, Ferrara M, Angelino E, Gnocchi VF et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest 2013; 123: 611–622.
17. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010; 142: 531–543.
18. Allen DL, Unterman TG. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am J Physiol Cell Physiol 2007; 292: C188-C199.
19. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle 2010; 1: 7–8.
20. Paul PK, Gupta SK, Bhatnagar S, Panguluri SK, Darnay BG, Choi Y et al. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J Cell Biol 2010; 191: 1395–1411.
21. Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia G et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 2009; 20: 604–612.
22. Deboer MD, Zhu X, Levasseur PR, Inui A, Hu Z, Han G et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 2008; 149: 827–835.
23. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007; 13: 3264–3268.
24. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908–913.
25. Granado M, Priego T, Martin AI, Villanua MA, Lopez-Calderon A. Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle. Am J Physiol Endocrinol Metab 2005; 289: E1007–E1014.
26. Sugiyama M, Yamaki A, Furuya M, Inomata N, Minamitake Y, Ohsuye K et al. Ghrelin improves body weight loss and skeletal muscle catabolism associated with angiotensin II-induced cachexia in mice. Regul Pept 2012; 178: 21–28.
27. Hiura Y, Takiguchi S, Yamamoto K, Kurokawa Y, Yamasaki M, Nakajima K et al. Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients. Int J Clin Oncol 2012; 17: 316–323.
28. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399–412.
29. Zhang G, Jin B, Li YP. C/EBPbeta mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting. EMBO J 2011; 30: 4323–4335.
30. Sun YS, Ye ZY, Qian ZY, Xu XD, Hu JF. Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J Exp Clin Cancer Res 2012; 31:81.
31. Stephens NA, Gallagher IJ, Rooyackers O, Skipworth RJ, Tan BH, Marstrand T et al. Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome medicine 2010; 2: 1.
32. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005; 19: 362–370.
33. Clavel S, Siffroi-Fernandez S, Coldefy AS, Boulukos K, Pisani DF, Derijard B. Regulation of the intracellular localization of Foxo3a by stress-activated protein kinase signaling pathways in skeletal muscle cells. Mol Cell Biol 2010; 30: 470–480.
34. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010; 429: 403–417.
35. McClung JM, Judge AR, Powers SK, Yan Z. p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol 2010; 298: C542–C549.
36. Kim J, Won KJ, Lee HM, Hwang BY, Bae YM, Choi WS et al. p38 MAPK participates in muscle-specific ring finger 1-mediated atrophy in cast-immobilized rat gastrocnemius muscle. The Korean Journal of Physiology & Pharmacology: Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology 2009; 13: 491–496.
37. Filigheddu N, Gnocchi VF, Coscia M, Cappelli M, Porporato PE, Taulli R et al. Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. Mol Biol Cell 2007; 18: 986–994.
38. Morissette MR, Cook SA, Buranasombati C, Rosenberg MA, Rosenzweig A. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol 2009; 297: C1124-C1132.
39. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009; 296: C1258–C1270.
40. Allen DL, Cleary AS, Hanson AM, Lindsay SF, Reed JM. CCAAT/enhancer binding protein-delta expression is increased in fast skeletal muscle by food deprivation and regulates myostatin transcription in vitro. Am J Physiol Regul Integr Comp Physiol 2010; 299: R1592–R1601.
41. Layne MD, Farmer SR. Tumor necrosis factor-alpha and basic fibroblast growth factor differentially inhibit the insulin-like growth factor-I induced expression of myogenin in C2C12 myoblasts. Exp Cell Res 1999; 249: 177–187.
42. Penna F, Costamagna D, Fanzani A, Bonelli G, Baccino FM, Costelli P. Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One 2010; 5: e13604.
43. Zhang W, Zhao L, Mulholland MW. Ghrelin stimulates myocyte development. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 2007; 20: 659–664.
44. Fanzani A, Zanola A, Rovetta F, Rossi S, Aleo MF. Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems. Toxicol Appl Pharmacol 2011; 250: 312–321.
45. Sakai H, Sagara A, Arakawa K, Sugiyama R, Hirosaki A, Takase K et al. Mechanisms of cisplatin-induced muscle atrophy. Toxicol Appl Pharmacol 2014; 278: 190–199.
46. Sun Y, Garcia JM, Smith RG. Ghrelin and growth hormone secretagogue receptor expression in mice during aging. Endocrinology 2007; 148: 1323–1329.
47. Sheriff S, Kadeer N, Joshi R, Friend LA, James JH, Balasubramaniam A. Des-acyl ghrelin exhibits pro-anabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats. Mol Cell Endocrinol 2012; 351: 286–295.
48. Gershon E, Vale WW. CRF type 2 receptors mediate the metabolic effects of ghrelin in C2C12 cells. Obesity (Silver Spring) 2014; 22: 380–389.
49. Cassoni P, Papotti M, Catapano F, Ghe C, Deghenghi R, Ghigo E et al. Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue. J Endocrinol 2000; 165: 139–146.
50. Cassoni P, Papotti M, Ghe C, Catapano F, Sapino A, Graziani A et al. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab 2001; 86: 1738–1745.
51. Hanada T, Toshinai K, Kajimura N, Nara-Ashizawa N, Tsukada T, Hayashi Y et al. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun 2003; 301: 275–279.
52. Wang W, Andersson M, Iresjo BM, Lonnroth C, Lundholm K. Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia. Int J Oncol 2006; 28: 1393–1400.